Status In progress
Process STA
ID number 591

Provisional Schedule

Final appraisal determination 12 February 2018 - 26 February 2018
Expected publication 21 March 2018

Project Team

Project lead Jeremy Powell

Email enquiries

Consultees

Companies sponsors Eusapharma Ltd
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Kidney Cancer Support Network
  Kidney Cancer UK
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Associated guideline groups None
Associated public health groups None
Comparator companies Bristol-Myers Squibb (nivolumab)
  Novartis Pharmaceuticals (everolimus, interleukin-2, pazopanib) confidentiality agreement not signed
  Pfizer (axitinib, sunitinib)
  Roche Products (interferon alfa 2a)
General commentators British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
Relevant research groups The Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
04 January 2018 Committee meeting: 3
07 December 2017 We have received further information from the company that requires consideration by the Appraisal Committee. We have therefore agreed to suspend the appeal stage of this appraisal. This will allow the company to submit, and the Appraisal Committee to consider, the new evidence at their meeting on 4 January 2018. Please note the additional Committee meeting date.
20 September 2017 Committee meeting: 2
11 August 2017 - 04 September 2017 Appraisal consultation
12 July 2017 Committee meeting: 1
09 February 2017 Invitation to participate
08 June 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance